Newly developed retatrutide, a twin -action drug targeting simultaneously GLP-1 and GIP receptors, is sparking considerable interest within the weight loss community. Initial clinical studies have shown significant reductions in body weight and gains in health markers for individuals with obesity . Scientists believe this unique approach could … Read More